BAN2401 Study to Assess New Alzheimer’s Treatment

If you or a loved one are experiencing signs of early Alzheimer’s disease, there may soon be treatment and hope on the horizon. First Choice Neurology is participating in an FDA-approved Phase III clinical trial to determine the benefit of an experimental product, BAN2401.   What is BAN2401 for Alzheimer’s? BAN2401 is a new class …

BAN2401 Study to Assess New Alzheimer’s Treatment Read More »